Ileocaecal resection has traditionally been reserved for the treatment of biologic-refractory inflammatory, fibrostenotic or fistulizing Crohn's disease of the terminal ileum. Now, for the first time, this surgical approach has been investigated as an initial treatment for steroid or immunomodulator-refractory Crohn's ileitis, in comparison with anti-TNF therapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Antunes, O. et al. Treatment algorithms in Crohn's — up, down or something else? Best Pract. Res. Clin. Gastroenterol. 28, 473–483 (2014).
Ponsioen, C. Y. et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol. Hepatol. http://dx.doi.org/10.1016/S2468-1253(17)30248-0 (2017).
Cosnes, J. et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm. Bowel Dis. 8, 244–250 (2002).
Mao, E. J. et al. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Aliment. Pharmacol. Ther. 45, 3–13 (2017).
Strong, S. et al. Clinical practice guideline for the surgical management of Crohn's disease. Dis. Colon Rectum 58, 1021–1036 (2015).
D'Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660–667 (2008).
Khanna, R. et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 386, 1825–1834 (2015).
Van Assche, G. et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am. J. Gastroenterol. 106, 1594–1602 (2011).
Holubar, S. D. et al. Anti-tumor necrosis factor-α antibody therapy management before and after intestinal surgery for inflammatory bowel disease: a CCFA position paper. Inflamm. Bowel Dis. 21, 2658–2672 (2015).
Appau, K. A. et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J. Gastrointest. Surg. 12, 1738–1744 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.S. received honorarium from Abbvie (consultant, speaker and education grant), Janssen (consultant and education grant) and Takeda (consultant, research grant).
PowerPoint slides
Rights and permissions
About this article
Cite this article
Shen, B. Step-up vs top-down therapy for Crohn's disease: medicine vs surgery. Nat Rev Gastroenterol Hepatol 14, 693–695 (2017). https://doi.org/10.1038/nrgastro.2017.139
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2017.139
This article is cited by
-
Ileitis terminalis Crohn – Ist die primäre Operation die bessere Therapie?
Der Chirurg (2021)
-
Hepatic mosaic enhancement pattern correlates with increased inflammatory activity and adverse therapeutic outcomes in patients with Crohn’s disease
Abdominal Radiology (2021)
-
Prevalence and predictors of surgical site infections after bowel resection for Crohn’s disease: the role of dual-ring wound protector
International Journal of Colorectal Disease (2019)
